The Beauty Health Company (SKIN) Smashes Q2 Expectations With Surprise Profit, $78.2M Revenue

Recent Q2 2025 results exceeded expectations, fueling renewed investor interest. The business reported revenue of $78.2 million and EPS of $0.03, surpassing the forecasted loss of $0.06, with gross margins holding at 62.8%. Analyst optimism grew, with TD Cowen raising its price target from $2.00 to $2.50, citing CEO-led strategic efforts in device sales and consumables innovation. Jefferies and Roth/MKM similarly upgraded their targets, highlighting improved sales and cost management.

A key driver of growth is The Beauty Health Company (NASDAQ:SKIN)’s focus on provider engagement and innovation. Beauty Health recently launched HydraFacial Advisory Councils and an Ambassador Network to gather feedback from clinic partners and ambassadors. This initiative aims to enhance product development and strengthen brand loyalty, with new booster launches expected later this year targeting mid-60s margins at price points of $220–$345. For investors looking at resilience in consumer health and wellness names, SKIN is increasingly discussed among the best bear market stocks given its steady margins and expanding consumables model.

Strategically, the firm continues to expand its consumable and back-bar product lines, with several rollouts planned for Q4 2025. It has also reinforced its convertible notes via a supplemental indenture, clarifying asset rights and reducing risk for creditors.

While we acknowledge the potential of SKIN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW